C&R Research Inc. (KOSDAQ:359090)

South Korea flag South Korea · Delayed Price · Currency is KRW
779.00
-4.00 (-0.51%)
At close: Apr 28, 2026
-26.23%
Market Cap 44.77B
Revenue (ttm) 64.98B
Net Income (ttm) 2.59B
Shares Out 57.47M
EPS (ttm) 45.00
PE Ratio 17.31
Forward PE n/a
Dividend 10.00 (1.28%)
Ex-Dividend Date Dec 29, 2025
Volume 112,854
Average Volume 101,256
Open 778.00
Previous Close 783.00
Day's Range 755.00 - 790.00
52-Week Range 733.00 - 1,178.00
Beta 0.12
RSI 41.75
Earnings Date May 15, 2026

About C&R Research

C&R Research Inc. engages in the of clinical development for pharmaceuticals and medical devices. The company’s therapeutic area comprises oncology, cardiovascular, endocrinology, dermatology, central nervous system, ophthalmology, and rare disease.The company was founded in 1997 and is based in Seoul, South Korea. [Read more]

Industry Commercial Physical and Biological Research
Founded 1997
Employees 510
Stock Exchange KOSDAQ
Ticker Symbol 359090
Full Company Profile

Financial Performance

In 2025, C&R Research's revenue was 64.98 billion, an increase of 8.87% compared to the previous year's 59.69 billion. Earnings were 2.59 billion, a decrease of -32.64%.

Financial Statements

News

There is no news available yet.